Ipilimumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted ipilimumab, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 15.1 years separate the first record, 1 Jun 2011 at AWMSG (Wales), from the most recent, 28 Jul 2026 at ZIN (Netherlands).
NICE (England) changed its position: restricted on 12 Dec 2012, recommended by 23 Jul 2014.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 15 of 58 records date from 2023 or later.
7 distinct indication wordings are recorded for ipilimumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 58 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ipilimumab, on 1 Jun 2011; CIPM (Spain) did not open a file until 25 Oct 2021 — an unusually long tail of 10.3 years between the earliest and latest system to look at it.
The record arrives in waves: 15 separate years each carry two or more decisions, spread across 15 years in total.
10 of the 14 agencies here assessed ipilimumab more than once, NYE METODER (Norway) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
ipilimumab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ipilimumab reads 25 recommended, 14 not recommended, 6 restricted and 4 no benefit, with 9 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 17 Jun 2026 | Indicaciones terapéuticas autorizadas: Melanoma YERVOY en monoterapia o en combinación con nivolumab está indicado para … | not financed by the SNS · art. 92 d | source |
| AIFA (Italy) | 27 Apr 2026 | YERVOY in associazione a nivolumab è indicato per il trattamento di pazienti adulti con carcinoma del colon-retto con de… | fully innovative · reimbursed class H | source |
| AOTMIT (Poland) | 17 Nov 2025 | programu lekowego B.5. „Leczenie chorych na raka wątrobowokomórkowego (ICD-10 C22.0) lub raka dróg żółciowych (ICD-10: C… | recommended conditionally | source |
| ZIN (Netherlands) | 30 Aug 2024 | Advies - vergoed ipilimumab (Yervoy®) in combinatie met nivolumab (Opdivo®) voor de behandeling van een bepaalde vorm va… | advice published (sluis) | source |
| NYE METODER (Norway) | 13 Jan 2021 | LUNGEKREFT - Førstelinjebehandling av metastatisk ikke-småcellet lungekreft hos pasienter med høy mutasjonsbyrde i tumor… | decision recorded | source |
53 further decisions for ipilimumab, across 14 agencies, are not shown here. They include the most recent record on file, 28 Jul 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 46 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 58 decisions for ipilimumab from 14 agencies, 2011 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.